Lin28/let-7 axis in breast cancer

Area of Science:

• Molecular Oncology
• MicroRNA Biology
• Cancer Therapeutics

Background:

• Let-7 microRNAs function as tumor suppressors, with their diminished expression correlating with poor prognosis in breast cancer.
• Lin28A and Lin28B proteins are frequently overexpressed in breast cancer, inversely correlating with let-7 levels and Wnt signaling dysregulation.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying the Lin28A/Lin28B-let-7 microRNA axis in breast cancer.
• To explore the role of this axis in breast carcinogenesis, metastasis, and therapeutic resistance.
• To identify potential therapeutic strategies targeting this pathway.

Main Methods:

• Review of existing literature on let-7 microRNAs, Lin28A, Lin28B, and Wnt signaling in breast cancer.
• Analysis of molecular interplay and cellular compartments involved in let-7 biogenesis inhibition.
• Examination of oncogene regulation by let-7 and its clinical implications across breast cancer subtypes.

Main Results:

• Lin28A and Lin28B inhibit let-7 microRNA biogenesis, leading to oncogene overexpression (e.g., K-ras, C-myc, SOX-2).
• Lin28A overexpression is linked to reduced let-7 in ER+, ER-, and HER2+ breast cancers.
• Lin28B overexpression with reduced let-7 is specific to triple-negative breast cancer.

Conclusions:

• The Lin28A/Lin28B-let-7 axis is a critical regulator of breast cancer progression, metastasis, and treatment resistance.
• Targeting let-7 microRNAs, their mimics, or Lin28A/Lin28B inhibitors presents promising therapeutic avenues for breast cancer treatment.